• Regulatory NewsRegulatory News

    EMA: No New Patients Should Start Treatment With Lilly’s Lartruvo

    The European Medicines Agency (EMA) on Wednesday told doctors that no new patients should begin treatment with Eli Lilly’s Lartruvo (olaratumab) because a recent study found it is not more effective in combination with doxorubicin for patients with soft tissue cancer when compared to doxorubicin alone. The EMA warning comes just five days after Lilly announced that the Phase 3 study had failed. “Specifically, the study did not meet the primary endpoints of overall ...